| Ulcerative Colitis
Tremfya vs Zeposia
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Tremfya vs Zeposia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZeposia has a higher rate of injection site reactions vs Tremfya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zeposia but not Tremfya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tremfya
Zeposia
At A Glance
Subcutaneous / Intravenous
Every 4-8 weeks
Interleukin-23 antagonist
Oral
Once daily
S1P receptor modulator
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ulcerative Colitis
- Crohn Disease
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Ulcerative Colitis
Dosing
Psoriasis vulgaris Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.
Arthritis, Psoriatic Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD.
Ulcerative Colitis Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.
Crohn Disease Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome, Ulcerative Colitis Initiate with 7-day titration (0.23 mg once daily days 1-4, 0.46 mg once daily days 5-7); maintenance dose 0.92 mg orally once daily starting day 8; patients with mild or moderate hepatic impairment (Child-Pugh class A or B) take 0.92 mg once every other day after titration.
Contraindications
- History of serious hypersensitivity reaction to guselkumab or to any of the excipients
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months
- Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
- Severe untreated sleep apnea
- Concurrent use of a monoamine oxidase (MAO) inhibitor
Adverse Reactions
Most common (>=1%) Upper respiratory infections (14.3%), headache (4.6%), injection site reactions (4.5%), arthralgia (2.7%), diarrhea (1.6%), gastroenteritis (1.3%), tinea infections (1.1%), herpes simplex infections (1.1%).
Serious Serious infections occurred in <=0.2% in plaque psoriasis trials through Week 16. In ulcerative colitis trials, serious infections occurred in 0.8% with TREMFYA vs. 0% with placebo (44-week trial) and 1.8% vs. 0.7% (24-week trial). In Crohn's disease, serious infections occurred in 1.5% with TREMFYA vs. 0% with placebo.
Postmarketing Hypersensitivity including anaphylaxis, rash.
Most common (>=4%) Upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, hypertension (MS); liver test increased, upper respiratory infection, headache (UC)
Serious Infections, progressive multifocal leukoencephalopathy, bradyarrhythmia and AV conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, cutaneous malignancies, posterior reversible encephalopathy syndrome
Postmarketing Liver injury
Pharmacology
Guselkumab is a human monoclonal IgG1 lambda antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23) and inhibits its interaction with the IL-23 receptor, thereby inhibiting the release of proinflammatory cytokines and chemokines.
Ozanimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in MS and ulcerative colitis is unknown but may involve reduced lymphocyte migration into the CNS and intestine.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tremfya
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
Zeposia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Tremfya
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (5/8) · Qty limit (5/8)
Zeposia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Tremfya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zeposia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Psoriatic Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Zeposia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TremfyaView full Tremfya profile
ZeposiaView full Zeposia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.